Carglumic acid

Product NDC
68475-006
11-digit product format
684750006
Labeler code
68475
Product ID
68475-006_55e79bd0-56bd-4095-aa7e-942b3e5c1b40
Type
HUMAN PRESCRIPTION DRUG
Nonproprietary name
Carglumic acid
Dosage form
TABLET, FOR SUSPENSION
Route
ORAL
Labeler
Navinta LLC
Application
ANDA213395
Marketing category
ANDA
Marketing start
2022-08-01
Substance
CARGLUMIC ACID
Active strength
200 mg/1
Pharmacologic classes
Carbamoyl Phosphate Synthetase 1 Activator [EPC], Carbamoyl Phosphate Synthetase 1 Activators [MoA]
NDC exclude flag
No
Listing certified through
2026-12-31
Current FDA listing
Yes

Orange Book products#

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A213395-001CARGLUMIC ACIDCARGLUMIC ACID200MGTABLET, FOR SUSPENSION / ORALAB2022-06-22

Therapeutic equivalence codes#

Application-product, TE code table
Application-productTE code
A213395-001AB

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Carglumic acidCARGLUMIC ACIDNavinta LLC59e73eb8-edf8-4fad-93c2-deb6b23497f82024-03-23Adverse reactionsExact identifier

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

adverse reactions

6 ADVERSE REACTIONS NAGS deficiency : Most common adverse reactions (≥13%) are vomiting, abdominal pain, pyrexia, tonsillitis, anemia, diarrhea, ear infection, infections, nasopharyngitis, hemoglobin decreased, and headache. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Navinta LLC at 1-609-883-1135, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Acute and Chronic Hyperammonemia due to NAGS Deficiency In a retrospective case series of 23 NAGS deficiency patients treated with Carglumic acid tablets for oral suspension, 17 of the 23 patients reported an adverse reaction. The most common adverse reactions (occurring in ≥ 13% of patients) were vomiting, abdominal pain, pyrexia, tonsillitis, anemia, diarrhea, ear infection, infections, nasopharyngitis, hemoglobin decreased, and headache. Table 1 summarizes adverse reactions occurring in 2 or more patients treated with carglumic acid tablets for oral suspension. Table 1: Adverse Reactions Reported in ≥ 2 Patients with NAGS deficiency Treated with Carglumic Acid Tablets for Oral Suspension in the Retrospective Case Series Adverse Reaction Number of Patients (N) (%) Vomiting 6 (26) Abdominal pain 4 (17) Pyrexia 4 (17) Tonsillitis 4 (17) Anemia 3 (13) Diarrhea 3 (13) Ear infection 3 (13) Infections 3 (13) Nasopharyngitis 3 (13) Hemoglobin decreased 3 (13) Headache 3 (13) Dysgeusia 2 (9) Asthenia 2 (9) Hyperhidrosis 2 (9) Influenza 2 (9) Pneumonia 2 (9) Weight decreased 2 (9) Anorexia 2 (9) Somnolence 2 (9) Rash 2 (9) 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of Carglumic acid tablets for oral suspension. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or to establish a causal relationship to drug exposure. Psychiatric disorders : mania Skin and subcutaneous tissue disorders : pruritus, rash including rash erythematous, rash maculopapular, rash pustular

adverse reactions table

Table 1: Adverse Reactions Reported in ≥ 2 Patients with NAGS deficiency Treated with Carglumic Acid Tablets for Oral Suspension in the Retrospective Case Series Adverse Reaction Number of Patients (N) (%) Vomiting 6 (26) Abdominal pain 4 (17) Pyrexia 4 (17) Tonsillitis 4 (17) Anemia 3 (13) Diarrhea 3 (13) Ear infection 3 (13) Infections 3 (13) Nasopharyngitis 3 (13) Hemoglobin decreased 3 (13) Headache 3 (13) Dysgeusia 2 (9) Asthenia 2 (9) Hyperhidrosis 2 (9) Influenza 2 (9) Pneumonia 2 (9) Weight decreased 2 (9) Anorexia 2 (9) Somnolence 2 (9) Rash 2 (9)

Additional Listing Data#

Finished product
Yes
Brand name base
Carglumic acid
Listing expiration
2026-12-31

Active Ingredients#

Ingredient, Strength table
IngredientStrength
CARGLUMIC ACID200 mg/1

Harmonized Identifiers#

Field, Values table
FieldValues
Unii5L0HB4V1EW
Rxcui905390

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
9860662a-dd40-3c34-05c2-84feaf18f015Product name320230314

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
68475-006-01Carglumic acid5 in 1 BOTTLETABLET, FOR SUSPENSION53
68475-006-02Carglumic acid60 in 1 BOTTLETABLET, FOR SUSPENSION603

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
68475-006CARGLUMIC ACID TABLET, FOR SUSPENSION [NAVINTA LLC]3Current NDC, Legacy NDC, 2 package rows20240426_59e73eb8-edf8-4fad-93c2-deb6b23497f8.zip

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYDailyMedSPL version
905390carglumic acid 200 MG Tablet for Oral SuspensionPSN59e73eb8-edf8-4fad-93c2-deb6b23497f83
905390carglumic acid 200 MG Tablet for Oral SuspensionSCD59e73eb8-edf8-4fad-93c2-deb6b23497f83
905390carglumic acid 200 MG Dispersible Tablet for Oral SuspensionSY59e73eb8-edf8-4fad-93c2-deb6b23497f83

Packages#

Package NDC, 11-digit format, Description table
Package NDC11-digit formatDescriptionMarketing startMarketing endSampleExclude flagStatus
68475-006-01684750006015 TABLET, FOR SUSPENSION in 1 BOTTLE (68475-006-01) 2022-08-010000-00-00NoNoCurrent
68475-006-026847500060260 TABLET, FOR SUSPENSION in 1 BOTTLE (68475-006-02) 2022-08-010000-00-00NoNoCurrent